Publications by the researcher in collaboration with Roberto Rodríguez Jiménez (21)

2022

  1. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1

2021

  1. Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis

    Schizophrenia Research, Vol. 236, pp. 19-28

  2. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 164-176

  3. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

    Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

  2. Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis

    Psychological Medicine, Vol. 50, Núm. 16, pp. 2702-2710

  3. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2019

  1. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

  2. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

  3. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

    Psychological Medicine, Vol. 48, Núm. 13, pp. 2247-2256

  4. Smoking does not impact social and non-social cognition in patients with first episode psychosis

    Schizophrenia Research, Vol. 199, pp. 64-74

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

  2. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients

    European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656

  3. Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset

    Journal of Clinical Psychiatry, Vol. 78, Núm. 9, pp. 1414-1422

  4. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study

    Schizophrenia Research, Vol. 189, pp. 84-90

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

  2. Opposite cannabis-cognition associations in psychotic patients depending on family history

    PLoS ONE, Vol. 11, Núm. 8

2015

  1. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis: The PEPsCog Study

    Schizophrenia Research, Vol. 164, Núm. 1-3, pp. 65-73

2014

  1. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178